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Abstract 
The objective of this review was to summarise the costs of TB diagnosis and treatment in HIV infected patients and to 
assess the methodological quality of these studies. We include cost, cost-effectiveness and cost-utility studies that 
reported primary costing data, conducted worldwide and published between 1990 and August 2016. We retrieved 
papers in PubMed, EMBASE, EconLit, CINAHL plus, and LILACS databases. The quality assessment was performed 
using two guidelines, “Consolidated Health Economic Evaluation Reporting Standards” and “The Tool to Estimate 
Patient’s Costs”. TB diagnosis was reported as cost per positive result or per suspect case. TB treatment was reported 
as: cost of TB drugs, TB/HIV hospitalisation and treatment. We analysed the data per level of TB/HIV endemicity and 
perspective of analysis. We included 34 articles, 24 addressing TB/HIV treatment and 10 TB diagnosis. Most of the 
studies were carried out in high TB/HIV burden countries (82%). The cost of TB diagnosis per suspect case varied from 
USD 0.5 for sputum smear microscopy to USD 175 for intensified case finding. The cost of TB/HIV hospitalisation 
were higher in low/medium burden countries than in high burden countries (USD 75,406 vs USD 2,474). TB/HIV co-
infection presented higher costs than TB from the provider perspective (USD 814 vs USD 604 vs USD 454). Items such 
as “choice of discount rate”, “patient interview procedures” and “methods used for valuing indirect costs” did not 
achieve a good score in the quality assessment. 
  
1. Introduction 
The World Health Organization (WHO) estimates 1.1 people worldwide are living with tuberculosis (TB) and human 
immunodeficiency virus (HIV) co-infection 1. Among HIV  patients the prevalence of co-infection can reach 
approximately 31% in African countries 2. Although the number of deaths due to TB/HIV co-infection has been falling, 
TB is still the main cause of death for HIV patients 1. Besides the epidemiological burden of the concurrent TB and HIV 
epidemic, TB diagnosis and treatment for the care of HIV can be costly to the health system, patients and their families. 
High costs of diagnosis and treatment can be a barrier for universal care of TB in HIV patients and an obstacle to 
achieve the end of both the epidemic by 2030 as advocated by the United Nation Sustainable Development Goals 3.  
Within the context of TB diagnosis for HIV patients, interventions can include multiple interacting elements, with a 
combination of diagnosis algorithms.  The treatment of TB can also present some level of complexity in HIV patients. 
Co-infected patients can present more side effects during chemotherapy and, have higher relapse rates 4,5. 
Understanding the nature and dynamic of these costs is paramount for robust costs estimates. Also, an assessment on 
whether appropriate methods of economic evaluation are being undertaken is key for the scaling up interventions that 
can be cost-effective or cost-saving to the whole society.  
Three previous reviews have explored the economics of TB/HIV co-infection and these focused mainly on African 
countries.  These studies have a different focus from the current review such as, costs of expansion of interventions for 
TB/HIV patients and cost-effectiveness of delivering TB and HIV services 6–8. So far, no studies have been published 
that either synthesise the different costs of TB/HIV co-infection or that assess the methodological quality of these 
studies. In addition, there has been no assessment to date on whether information on costs is widely available, especially 
for countries with high burden of TB/HIV co-infection. The aim of this article is therefore to undertake a systematic 
literature review to summarise the costs of diagnosis and treatment of TB/HIV by countries levels of endemicity, and to 
assess the methodological quality of these studies.  
2. Methodology 
This systematic review was designed and conducted according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis (PRISMA) recommendations 9. A protocol for this review is registered at Prospero – International 
Prospective Register of Systematic Reviews - CRD42015020730. 
2.1 Inclusion and exclusion criteria 
All cost, cost-effectiveness and cost-utility studies that reported primary costing data on the diagnosis of TB in HIV 
patients, including case detection, and TB/HIV co-infection treatment were included in this review. Studies addressing 
costs of treatment and diagnosis of TB or HIV alone, but that included a sample of TB/HIV co-infected patients and 
presented the cost disaggregate were also selected and assessed. Only peer-reviewed papers, published between 1990 
and August 2016, conducted worldwide and written in English, Spanish or Portuguese were included. Papers using only 
secondary data on costs and only including the cost of prevention with IPT were excluded. References reported in 
systematic reviews were screened to identify further studies not captured in the literature search.  
2.2 Search strategy  
We applied the MeSH (Medical Subject Headings) terms using the following key words “HIV OR HIV Infections” OR 
“Tuberculosis OR Mycobacterium tuberculosis” OR “coinfection” AND “costs and cost analysis OR cost allocation OR 
cost of illness OR health care costs OR health expenditures” to search the papers. We retrieved papers in PubMed, 
EMBASE, EconLit, CINAHL plus, and LILACS. Two reviewers (NTSF and ACS) independently selected the studies 
by title and abstract. A list of these independently selected studies was then compared. The reference list of retrieved 
studies was also reviewed to identify studies not captured by the search strategy. The literature search was undertaken 
on 11 August 2016.  
2.3 Data extraction 
Two reviewers (NTSF and AC) extracted independently the data in an Excel spreadsheet. A third reviewer (ACS) 
discussed discordances and decision was agreed by consensus. Mendeley software was used to manage all selected 
studies. We extracted: reference, country, endemicity of TB/HIV co-infection, geographical area, period of data 
collection, type of intervention, study design, level of treatment (inpatient, outpatient), period of cost analysis (pre-
diagnosis, treatment), type of costs, source of costing data, perspective of analysis and costs results.  
2.4 Quality assessment 
The quality assessment of studies was based on two guidelines “Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS)” and “The tool to Estimate Patient’s Costs (TBCA)” 10,11. The analysis was mainly focused on the 
methods through the assessment of the following criteria: target population; setting and location; study perspective; time 
horizon; discount rate; cost estimation methods; period of data collection, currency, price date, and conversions; 
methods used for valuing indirect costs; mean values of estimated costs; patient interview procedures, instrument and 
source of data collection. Studies were then assessed based on the proportion they reached pre-established criteria. 
2.5 Data analysis  
Costs were first inflated to 2015 prices using USD inflation rates 12. Then, costs reported in local currency were 
converted to US Dollars using exchange rates as reported in the OANDA website13. Results were first presented as two 
main themes: (1) costs of TB diagnosis in HIV patients and (2) costs of treatment of TB/HIV co-infection. Sub-analyses 
were then presented reflecting the country burden of disease as defined by WHO TB report, 2015: high TB/HIV burden 
and low/medium TB/HIV burden country 14. The analysis also took into account the perspective of cost (provider, 
patients and societal) and period of cost analysis (pre-diagnosis and treatment).   
To analyse the cost of TB diagnosis in HIV patients, we first extracted the cost per positive result and/or cost per 
suspect case. We grouped the diagnostic algorithms in six categories: (1) Sputum culture; (2) Other cultures (i.e. pleura, 
bone marrow) (3) Intensified Case Finding (ICF) (4) Histology (i.e. pleura, bone marrow, liver) (5) Sputum smear 
microscopy and (6) Others smears (i.e. fluid, urine). We presented the results in box and whisker charts to show the 
range, the interquartile (IQR) distribution of the costs, mean and median.  
To analyse the cost of TB/HIV co-infection treatment we extracted mean cost of the intervention analysed per cost 
perspective and period of cost analysis (pre-diagnosis and treatment). We extracted the following information, when 
available: cost of TB drugs for HIV patients, cost of TB/HIV hospitalisation and costs of TB/HIV treatment (inpatient 
plus outpatient treatment). We compared the cost of TB, TB/HIV and HIV categories, when possible. 
3. Results 
3.1 Selection, geographical distribution and scope of studies 
We found 7,807 potentially relevant articles and selected 100 full text papers for assessment. We excluded thirty-three 
articles because the cost data were not disaggregated between HIV only and TB/HIV patients. A further thirty-three 
articles were excluded due to absence of information about the study sample or insufficient reporting of costs, or use of 
secondary data, or the study design was not a cost study, and one study addressed the cost of HIV screening in TB 
patients. We included 34 articles with 24 addressing costs to treat TB/HIV co-infection and 10 addressing TB diagnosis 
in HIV patients. Most of the studies were carried out in high TB/HIV burden countries, 28 in total (Figure 1). Figure 2 
shows the distribution of the studies across the world based on the level of endemicity for TB/HIV co-infection. 
Although 41 countries were classified as high burden countries in the 2015 WHO list, information on costs was 
available only for 13 countries. Studies from high TB/HIV burden countries reported data mainly from African 
countries (n=20), especially South Africa, with nine studies, and Nigeria, with five studies. From the perspective of 
low/medium TB/HIV burden countries, the most frequent studies came from United States (n=3). 
Studies estimated the costs of several interventions for TB/HIV treatment and the costs of different TB diagnostic 
algorithms from the provider and societal perspective. Studies also covered costs for patients and their families, 
addressing direct medical and non-medical costs, indirect costs and estimates for catastrophic and coping strategies 
costs. Table S1 in the Supplementary file summarises the characteristics of these studies and presents their main results 
adjusted by inflation. 
3.2 Cost of TB diagnosis 
Ten studies addressed the cost of TB diagnosis in HIV patients and all of them analysed the costs from the provider 
perspective. Only one of these studies was conducted in a low/medium TB/HIV burden country, this study analysed a 
TB screening among HIV infected patient in Laos. The mean cost per suspect case of a screening through sputum smear 
microscopy by bleach method, and through Acid Fast Staining was 2 USD and 0.5 USD, respectively 15.    
Among those studies carried out in high burden countries 16–24, we found a variety of algorithms within the diagnostic 
groups. The ICF category was performed through chest x-ray screening 24; symptom screening plus sputum smear (SS), 
culture (SC) and chest x-ray (CXR) 17; symptom screening plus acid-fast bacilli (AFB) smear and PCR; symptom 
screening plus AFB smear and SC 22; light-emitting diode microscopy (LED) screening; gene Xpert screening 20; 
symptom screening plus CXR, AFB smear and SC18. The sputum culture category was performed using solid media and 
mycobacteria growth indicator tube (MGIT)21. Sputum smear category was performed through LED and Ziehl–Neelsen 
(ZN) light microscopy23. Finally, histology, other cultures and smear categories were performed in pleura, pleural fluid, 
bone marrow, urine and blood16.  The diagnostic category “other cultures” presented the higher mean costs per positive 
result (348 USD), followed by ICF (294 USD), histology (252 USD) other smears (149 USD) and sputum culture (81 
USD). For those studies, which reported the mean costs per suspect case, we only found the evaluation of two 
diagnostic categories, ICF (79 USD) and sputum smear (4 USD). Figures 3a and 3b show the mean, median and IQR 
interval of each diagnostic category. 
3.3 Costs of TB/HIV treatment 
Societal perspective: 
Three articles analysed the costs of treatment for TB/HIV co-infection from the societal perspective in high burden 
countries, 25–27  but one of them provided data only about TB drug costs in HIV patients 26. In Ethiopia, Mesfin et al 
(2010) analysed TB costs to seek care during the pre-diagnosis period and found similar cost for TB patients with or 
without HIV co-infection, 262 USD and 296 USD, respectively 25. Koening et al (2008) analysed the cost of ART 
provision in Haiti. The authors found that higher cost was associated with TB treatment, hospitalisation and change in 
ART regimen. Also, TB/HIV patients required more physician and nursing time. The mean total treatment cost of 
TB/HIV patient was 4,059 USD 27. Only one study was carried out in a low/medium TB/HIV burden country, USA, and 
the mean cost to treat TB/HIV co-infection was 10,300 USD 28. 
Provider perspective: 
Thirteen studies reported cost from the provider perspective disaggregated by TB/HIV status 25–27,29–38. Another study 
carried out in Haiti found the cost to treat TB/HIV patient as 22 USD, however it is not clear which cost components 
was included in the analysis 30.  One study carried out in Ethiopia analysed the costs during the pre-diagnosis period and 
found a cost 11.6 times higher for TB/HIV patients when compared with TB patients (348USD vs 33 USD) 25. During 
the treatment period, one study carried out in Sudan provided the mean cost of TB and TB/HIV hospitalisation, and 
found higher costs for the last category (1,152 USD vs 1,558 USD). The same  study also found higher costs of TB/HIV 
treatment (inpatient plus outpatient) when compared with TB patients (858 USD vs 604 USD) 34. Another study carried 
out in South Africa reported the mean cost only for TB/HIV outpatients (2,831 USD) 38.  
Overall, the mean cost of TB drugs for HIV patient was 91 USD and the mean treatment (inpatient plus outpatient), and 
hospitalisation cost of TB/ HIV patient were 814 USD and 2,474 USD, respectively. When compared with TB patients, 
TB/HIV patient presented higher mean costs for hospitalisation (2,474 USD vs 1,152 USD) and treatment (814 USD vs 
604 USD). Finally, the mean cost of TB/HIV hospitalisation in low/medium burden countries (USA and Portugal) was 
30 times higher than the mean cost of hospitalisation in high burden countries (table 1). 
Four  studies analysed the cost from provider perspective in low/medium TB/HIV burden countries 39–42. One study 
carried out in Peru analysed a program for integrated care of  TB/HIV patients and found a cost of 817 
USD/patient/year 41. Three other studies analysed the costs based on charges, the mean cost of TB/HIV hospitalisation 
was 75,407 USD39,40,42. Gomes et al (2003) also compared the hospitalisation cost for TB and TB/HIV in Portugal and 
found higher cost for the last category (11,560 vs 18,327) 40.  One study carried out in USA, analysed TB/HIV 
outpatient  cost, which was 1,186 USD 42. We could not find studies providing information about TB drug costs in HIV 
patients in low/medium burden countries. 
Patient/family perspective: 
Seven studies presented the results disaggregated by TB/HIV co-infection. All studies were carried out in high burden 
countries and four of them in Nigeria. 35,43–48. During the pre-diagnosis period three studies reported cost for TB and 
TB/HIV co-infection. The mean direct cost for TB and TB/HIV was 273 USD and 313 USD and the mean indirect cost 
was 76 USD and 147 USD, respectively. One of these studies carried out in Ethiopia also compared the cost for TB, 
TB/HIV and HIV categories. The mean direct cost was 639 USD, 783 USD and 1,417 USD for TB, TB/HIV and HIV, 
respectively. The mean indirect cost was 53 USD, 117 USD and 107 USD for TB, TB/HIV and HIV, respectively 44. 
During the treatment period six studies reported costs for TB and TB/HIV categories. The mean direct cost was 227 
USD and 278 USD for TB and TB/HIV, respectively. The mean indirect cost was 247 USD and 314 USD for TB and 
TB/HIV, respectively. One of these studies carried out in Nigeria also compared TB, TB/HIV and HIV mean direct 
cost, which was 508 USD, 780 USD and 489 USD, respectively 43. Overall, comparing TB/HIV and TB patients, we 
found similar direct costs during the pre-diagnosis and treatment period. However, TB/HIV patients experience higher 
indirect costs during the pre-diagnosis period. Comparing TB/HIV and HIV patients, we found higher mean direct costs 
for the last category during both pre-diagnosis and treatment period (table 2). 
3.4 Quality assessment 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 
We assessed 10 quality indicators using CHEERS recommendations. “Study perspective”, “period for resources 
estimation, quantities and unit costs”, “target population” “time horizon” and “cost estimation methods” achieved 
scores higher than 90%. The provider perspective was the most frequently adopted point of view for analyses, with 68% 
of the studies assessing the costs from this perspective. Two studies did not report the perspective of analysis; although 
their results suggest the costs were collected from a provider perspective. The “cost estimation methods” was clearly 
reported in 94% of papers and the ingredient approach was most common applied method - 78% of all studies. Other 
methods included expenditure approach (costs based on tariff fees, refund claim, charges), and extrapolation approach 
(when the cost of an intervention is extrapolated to the current analysed intervention). “Time horizon” covering the 
treatment period was stated in 62% of the papers, and 17% stated for both the pre-diagnosis and treatment period. The 
definition of TB treatment period varied among studies, with some covering different phases of the treatments. 
Another methodological requirement for cost analysis presented relatively high score in the quality assessment, 
“sources used for resource quantities and unity costs”, with 82% of studies reporting it. Less frequently reported 
methodological aspects include “values for main categories of estimated costs”, with 76% of studies reporting this 
aspect; “setting and location”, with 74%, and “methods for adjusting unit costs and currency conversion”, with 69%. 
(Table 3).  
3.4.2 The tool to Estimate Patient’s Costs (TBCA): 
We applied the TBCA protocol to analyse 10 studies which included costs for patients and their families in the cost 
analysis. A clear description of patient interview procedures was given in 67% of the studies.  
Questionnaires were applied to collect data on direct out-of-pocket expenditures, including fees, charges for tests and 
medicines, transport, food and accommodation, and indirect costs, defined as time and/or productivity lost due the 
disease. Two studies did not provide explanations either on the procedures to collect data on indirect costs 27,43 or have 
stated they have applied a questionnaire to collect direct and indirect costs, but have not explained the process of 
interviewing the patient (e.g. information contained in the questionnaire; adaptation of the questionnaire to local 
circumstance; training interview) 46.  Indirect costs covering losses in time and/or productivity for visiting or caring for 
patients, travelling to the medical service, waiting for consultation or due to hospitalisation and disability), were 
assessed in 9 papers (80%), and 67% of them described the methods used to value these costs. Ways to estimate and 
present indirect costs varied from studies.  Umar et al (2012) estimated the income loss from the difference in patient’s 
self-reported monthly income and household income for the periods before and during the illness 45. Other methods 
applied local labour cost, minimum wage or average wage rate per day/hour reported by patients to calculate indirect 
costs 25–28,48 (Table 4). Tables S2 and S3 in the Supplementary file give the detailed quality assessment of the articles. 
4. Discussion 
 
In our review, the cost of diagnostic tests per suspect case were estimated as cheaper as 0.5 USD for SSM, in Laos, and 
as expensive as 175 USD for the ICF algorithm through screening with gene Xpert test, in Malawi 15,20. We also found 
substantial variation within the same diagnostic groups/tests such as ICF, sputum culture and other cultures categories. 
Apart from differences in healthcare settings and systems, this variation in estimated costs might be also explained by 
the adoption of different aspects of costs components into the analysis. For example, some studies included training and 
overheads costs into their calculations while others did not. Furthermore, there are different costs and medical system 
within the countries. Thus, it may not be possible to simply compare cost analysis results across different countries. 
The costs of TB/HIV hospitalisation were considerably higher in low/medium burden countries when compared to high 
burden countries, 75,406 USD vs 2,474 USD, respectively. HIV prevalence, as well as these being high resource 
settings where all costs would be higher can explain differences in costs between low/middle and high burden countries. 
While this difference in estimates certainly reflect characteristics of health systems settings and type of treatment 
received, the methods for calculating costs may also be an important factor. In USA and Portugal, the estimates 
included charges as a proxy for costs; this approach clearly overestimates the cost figures for hospitalisation in that 
setting.   
We also found higher costs of TB/HIV co-infected patients when compared with TB patients from the provider 
perspective. The higher costs are highlighted in the hospitalisation care when the cost of TB/HIV was the double of TB 
patients. Considering inpatient plus outpatient care, the cost to treat TB/HIV patients was also the double to treat HIV 
other opportunistic infections. The higher cost for TB/HIV patients is possibly associated with higher relapse rates, 
more side effects due to the combination of ART and chemotherapy and, consequently, more frequent hospitalisations 
during the course of TB/HIV treatment.   
A considerable number of studies were excluded from this review (N = 33) because they presented their findings 
without separating TB outcomes for diagnosis and treatment for the population of HIV patients. While we understand 
studies have different objectives and they not necessarily should aim for the presentation of diseases outcomes in a 
separated manner, the results of this review clearly point for the gap in information about disaggregated data on the co-
infection TB/HIV for both, diagnosis and treatment. A notable piece of information when efforts are being made in 
order to scale-up and promote access to cost-effective alternatives for the diagnosis and treatment of TB in HIV patients 
for the elimination of both diseases 1,3.  
We also found a huge variation in costs among the studies addressing the patient perspective. Variation in costs can be 
explained by the use of different approaches to capture these costs, for example the human capital approach estimates 
time lost from employment by using the current salary wages, or caregiver time that can be valued using average hourly 
wages as a proxy. Although comparisons of indirect costs can become a difficult objective to be reached due to different 
methodologies applied, all these approaches allow for relatively straightforward data collection and easy adaptability of 
tools by countries, even though they are not free of limitations 49. 
Besides the expected variation in costs estimates, our review also found some important discrepancy in the 
methodological aspects of the reviewed studies. In spite of the fact that there is no universal checklist for costing 
analysis, a recent systematic review addressing TB costs used the same type of assessment 50. Our findings showed key 
economic principles are not being covered by all studies, with some items being covered by less than 90% of studies, 
such as, “methods for adjusting unit costs and currency conversion” and “choice of discount rate”, with the latter 
covering only 62% of the studies. The adjustment of costs by inflation and currency conversion, as obscure figures can 
result in costs estimates that are not robust enough to be taken into consideration in an economic analysis.  
Another important finding relates to the geographical distribution of the studies. Our results showed that more than 80% 
of studies were conducted in high TB/HIV burden countries. Nevertheless, 29 out of 41 high burden countries do not 
have any published cost data addressing TB/HIV costs, for either diagnosis or treatment. The purpose of the WHO list 
dividing countries by the burden of TB/HIV was to encourage global action on the co-infection and scale-up of 
collaborative activities addressing both diseases, including supporting discussions on costs 51. Our review shows that 
there are still important limitations on the generation of costing data to give support to the assessment of scaling up of 
interventions. Also, there is still a gap in terms of standardisation of methods used to capture a full cost evaluation.  
This review highlighted important conclusions on cost evaluations within the context of the co-infection TB/HIV. 
However, as our searches were limited to English, Portuguese and Spanish languages, we cannot be completely 
confident our review was comprehensive. Besides, the quality assessment showed that studies varied in terms of 
methodological rigour and so, generalisation of estimates should be taken with caution. 
Our review findings clearly point to the need of generation of data on costs estimates for diagnosis and treatment, in a 
disaggregated manner, especially for countries with a high burden of TB/HIV. We also call for the attention on more 
standardised economic methods to the collection and estimation of costs that can generate transparent, comprehensive, 
reliable, valid, and therefore more robust cost estimates, to support decision-making upon the introduction of new 
technologies or scale-up of the existing ones.   
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